alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
MEDIZONE CANADA LIMITED
                           55 West 200 North, Suite 2
                               Provo, Utah 84601

                NOTICE OF SPECIAL MEETING OF STOCKHOLDERS OF

                          MEDIZONE CANADA LIMITED

                         TO BE HELD JULY 20, 1998

TO ALL STOCKHOLDERS:

          NOTICE is hereby given that a special meeting of the stockholders of 
MEDIZONE CANADA LIMITED, a Utah corporation (the "Company"), has been called 
to be held on July 20, 1998, at 55 West 200 North, Suite 2, Provo, Utah 84601, 
at the hour of 5:00 o'clock p. m., Mountain Daylight Time, for the following 
purposes:

     1.   To consider and act upon a resolution of the Board of Directors to 
          change the domicile of the Company to the state of Nevada;

     2.   To conduct such other business as may properly come before the 
          meeting.

     The Board of Directors of MEDIZONE CANADA LIMITED has set 5:00 o'clock 
p.m. on July 10, 1998, as the record date for the purpose of determining the 
stockholders of the Company who shall be entitled to notice of the meeting.  
Certain members of management owning in excess of the number of shares 
necessary to adopt the resolution to be presented at the meeting regarding the 
change of domicile have agreed to vote in favor of such domicile change, and 
accordingly, no proxies are be solicited or are necessary.  


                                   MEDIZONE CANADA LIMITED

Provo, Utah
July 10, 1998
Exhibit 31
**CERTIFICATION**
I, Lee Ann Anderson, certify that:
     1. I have reviewed this Quarterly Report on Form 10-Q of San Juan BasinRoyalty Trust, for which TexasBank acts as Trustee;
     2. Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessary to makethe statements made, in light of the circumstances under which such statementswere made, not misleading with respect to the period covered by this report;
     3. Based on my knowledge, the financial statements, and other financialinformation included in this report, fairly present in all material respectsthe financial condition, distributable income and changes in trust corpus ofthe registrant as of, and for, the periods presented in this report;
     4. I am responsible for establishing and maintaining disclosure controlsand procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) forthe registrant and I have:
a) Designed such disclosure controls and procedures, or causedsuch disclosure controls and procedures to be designed under mysupervision, to ensure that material information relating to theregistrant, including its consolidated subsidiaries, is made known tome by others within those entities, particularly during the period inwhich this report is being prepared; b) Evaluated the effectiveness of the registrant’s disclosurecontrols and procedures and presented in this report my conclusionsabout the effectiveness of the disclosure controls and procedures, asof the end of the period covered by this report based on suchevaluation; and c) Disclosed in this report any change in the registrant’sinternal control over financial reporting that occurred during theregistrant’s most recent fiscal quarter (the registrant’s fourthfiscal quarter in the case of an annual report) that has materiallyaffected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and
     5. I have disclosed, based on my most recent evaluation of internalcontrol over financial reporting, to the registrant’s auditors:
a) All significant deficiencies and material weaknesses in thedesign or operation of internal control over financial reportingwhich are reasonably likely to adversely affect the registrant’sability to record, process, summarize and report financialinformation; and b) Any fraud, whether or not material, that involves persons whohave a significant role in the registrant’s internal control overfinancial reporting.
In giving the certifications in paragraphs 4 and 5 above, I have relied to theextent I consider reasonable on information provided to me by BurlingtonResources Oil & Gas Company LP.        Date:  November 8, 2004 By:  /s/ Lee Ann Anderson    Lee Ann Anderson    Vice President and Trust Officer, TexasBank
EXHIBIT 32.2





CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,


AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002








In connection with the Quarterly Report of Arête Industries, Inc. (the "Company") on Form 10-Q for the period ending March 31, 2008, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, John Herzog, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:





(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.







January 18, 2011
By:
/s/ John HerzogJohn Herzog, Interim Chief Financial Officer


A signed original of this written statement required by Section 906 has been provided to Arête Industries, Inc. and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
<PAGE>   1


                                                                      EXHIBIT 11

                           SI DIAMOND TECHNOLOGY, INC.

                     COMPUTATION OF (LOSS) PER COMMON SHARE



<TABLE>
<CAPTION>
                                                            Three months ended                       Year ended
                                                                December 31,                         December 31,
                                                        -----------------------------       ------------------------------
                                                           1999              1998               1999              1998
                                                        -----------       -----------       ------------      ------------
<S>                                                     <C>               <C>               <C>               <C>
Computation of income ( loss ) per common share:

   Net income (loss) applicable to common
          shareholders                                  $  (670,481)      $  (670,611)      $    977,971      $ (3,812,505)

   Weighted average number of common shares              53,651,504        44,796,030         51,188,385        37,207,122

   Net income (loss) per common share                   $     (0.01)      $     (0.01)      $       0.02      $      (0.10)

Computation of income ( loss ) per common
   share assuming full dilution:

   Net income (loss) applicable to common
      stockholders                                                                               977,971

   Plus: Income impact of assumed conversions
         Series G                                                                                140,163
         Interest                                                                                 21,832

   Income available to common stockholders                                                     1,139,966

   Weighted average number of common
          shares outstanding                                                                  51,188,385

   Plus incremental shares from dilutive securities
        Convertible preferred stock                                                            1,625,116
        Convertible notes payable                                                                635,168
        Warrants                                                                                 391,647
        Options                                                                                3,561,388

   Adjusted weighted average number of
         common shares outstanding                                                            57,401,654

Net income (loss) per common share                                                                  0.02
</TABLE>


No computation of diluted loss per common share is included for the 1998 periods
or for the three months ended December 31, 1999 because such computation results
in an antidilutive loss per common share.


                                    Page 60
[Federal Register Volume 74, Number 100 (Wednesday, May 27, 2009)]
[Notices]
[Page 25260]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-12192]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Complementary & Alternative Medicine; Notice 
of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. APP.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Complementary and 
Alternative Medicine Special Emphasis Panel; Basic and Preclinical 
Sciences.
    Date: June 14-16, 2009.
    Time: 6 p.m. to 5 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Residence Inn Bethesda, 7335 Wisconsin Avenue, Bethesda, 
MD 20814.
    Contact Person: Peter Kozel, PhD, Scientific Review Officer, 
NCCAM, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892-5475, 
301-496-8004, <a href="/cdn-cgi/l/email-protection#23484c59464f53634e424a4f0d4d4a4b0d444c55"><span class="__cf_email__" data-cfemail="fc97938699908cbc919d9590d2929594d29b938a">[email protected]</span></a>.

    Dated: May 15, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-12192 Filed 5-26-09; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<PAGE>

                                                                     EXHIBIT 8.1

        LIST OF SIGNIFICANT SUBSIDIARIES, JOINTLY CONTROLLED ENTITIES AND
                    ASSOCIATED COMPANIES OF BRILLIANCE CHINA
                       AUTOMOTIVE AS OF DECEMBER 31, 2005.

<TABLE>
<CAPTION>
                                                                       JURISDICTION
                                                                            OF
SUBSIDIARIES                                                          INCORPORATION
------------                                                          -------------
<S>                                                                   <C>
Shenyang Brilliance JinBei Automobile Co., Ltd.                       China
Ningbo Yuming Machinery Industrial Co., Ltd.                          China
Shenyang XingYuanDong Automobile Component Co., Ltd.                  China
Shenyang Jianhua Motors Engine Co., Ltd.                              China
Ningbo Brilliance Ruixing Auto Components Co., Ltd.                   China
Mianyang Brilliance Ruian Automotive Components Co., Ltd.             China
Shenyang JinBei Automotive Industry Holdings Company Ltd.             China
Shenyang XinJinBei Investment and Development Co., Ltd.               China
Shenyang Brilliance Dongxing Automotive Component Co., Ltd.           China
Shenyang JinDong Development Co., Ltd.                                China
Shenyang ChenFa Automobile Component Co., Ltd.                        China
Shanghai Hidea Auto Design Co., Ltd.                                  China
Shenyang Brilliance Power Train Machinery Co., Ltd.                   China
China Brilliance Automotive Components Group Limited                  Bermuda
Southern State Investment Limited                                     BVI
Beston Asia Investment Limited                                        BVI
Pure Shine Limited                                                    BVI
Key Choices Group Limited                                             BVI
Brilliance China Automotive Finance Ltd.                              BVI

JOINTLY CONTROLLED ENTITIES
Mianyang Xinchen Engine Co., Ltd.                                     China
Shenyang Xinguang Brilliance Automobile Engine Co., Ltd.              China
BMW Brilliance Automotive Ltd.                                        China

ASSOCIATED COMPANIES
Chongqing FuHua Automotive Sales Service Co., Ltd.                    China
Chongqing Baosheng Automotive Sale and Service Co., Ltd.              China
Shenyang Aerospace Mitsubishi Motors Engine Manufacturing Co., Ltd.   China
</TABLE>
TERRY WAYNE BUSLER

,

Appellant,

v.

STATE OF FLORIDA

,

Appellee

. IN THE DISTRICT COURT OF APPEAL FIRST DISTRICT, STATE OF FLORIDA

NOT FINAL UNTIL TIME EXPIRES TO
FILE MOTION FOR REHEARING AND
DISPOSITION THEREOF IF FILED

CASE NO. 1D 14

- 3572

_____________________________/

Opinion filed August 12, 2016.

An appeal from the Circuit Court for Duval County

. James L. Harrison , Judge

.

Nancy A. Daniels, Public Defender, and Megan Long, Assistant Public Defender,
Tallahassee , for Appellant.

Pamela Jo Bondi, Attorney General, and Thomas H. Duffy, Assistant Attorney General, Tallahassee , for Appellee.

PER CURIAM.

AFFIRMED.

ROWE

, KELSEY

, and JAY

, J J

. , CONCUR.